Openfund

CORDIS · DIOPTRA

EARLY DYNAMIC SCREENING FOR COLORECTAL CANCER VIA NOVEL PROTEIN BIOMARKERS REFLECTING BIOLOGICAL INITIATION MECHANISMS

Code
DIOPTRA
Programme
HORIZON
Call
HORIZON-MISS-2021-CANCER-02-01
Status
SIGNED
Period
2023-01-01 – 2026-12-31
Total cost (whole consortium)13 647 601 €
EU contribution (whole consortium)13 646 550 €
EU contribution to Bulgarian participants54 688 €

Official data · CORDIS · synced 2026-10-17 10:16 · official record

Participants

OrganisationsRoleCountryGrant
EREVNITIKO PANEPISTIMIAKO INSTITOUTO SYSTIMATON EPIKOINONION KAI YPOLOGISTONcoordinatorEL942 500 €
PROTAVIO MONOPROSOPI E.P.EparticipantEL4 648 750 €
CENTRE HOSPITALIER UNIVERSITAIRE DE LIEGEparticipantBE508 750 €
PANEPISTIMIO IOANNINONparticipantEL500 875 €
GENIKO ANTIKARKINIKO OGKOLOGIKO NOSOKOMEIO ATHINON O AGIOS SAVVASparticipantEL491 875 €
REGION SYDDANMARKparticipantDK477 210 €
ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINONparticipantEL474 000 €
FUNDACION BURGOS POR LA INVESTIGACION DE LA SALUDparticipantES452 500 €
Univerzitetni klinicni center MariborparticipantSI445 000 €
LINAC-PET SCAN OPCO LIMITEDparticipantCY418 750 €
KOMITEEN FOR SUNDHEDSOPLYSNINGparticipantDK389 250 €
EUROPEAN HOSPITAL AND HEALTHCARE FEDERATIONparticipantBE359 064 €
VILABS (CY) LTDparticipantCY331 250 €
NETCOMPANY S.A.participantLU325 000 €
MEDIZINISCHE UNIVERSITAT GRAZparticipantAT312 875 €
TECREANDO B.V.participantNL311 112 €
UAB TERAGLOBUSparticipantLT306 875 €
ARTHUR'S LEGAL BVparticipantNL301 250 €
AINIGMA TECHNOLOGIESparticipantBE272 500 €
CSI CENTER FOR SOCIAL INNOVATION LTDparticipantCY238 125 €
KLINICKA BOLNICA DUBRAVAparticipantHR226 562 €
D.TSAKALIDIS-G.DOMALIS OEparticipantEL220 000 €
CSCY COMPUTER SOLUTIONS CYPRUS LTDparticipantCY215 000 €
SMARTSOL SIAparticipantLV210 625 €
I2GROW INNOVATION TO GROW SRLparticipantIT203 125 €
BLOKS ZDRAVNI I SOTSIALNI GRIZHI EOODparticipantBG54 688 €
REGION MIDTJYLLANDparticipantDK9 040 €
SPHYNX TECHNOLOGY SOLUTIONS AGassociated partnerCH
CAMBRIDGE MEDICAL ACADEMY LTDassociated partnerUK
MARTEL GMBHassociated partnerCH

Description

DIOPTRA aims to introduce a front-line screening tool that will consider risk factors and protein biomarkers for pinpointing individuals at a high risk for colorectal cancer (CRC) incidence. Tissue & blood samples will be examined towards a discriminative set of prognostic proteins that are detectable via standard bloodwork and can indicate a need for further evaluation (i.e. colonoscopy). Other data (e.g. medical, behavioural) will also be considered as potential risk factors. Artificial intelligence (AI) will be leveraged for assessing prognostic power, while personalised behavioural change will be promoted based on modifiable risk factors. Given the low citizen participation on CRC screening across EU, DIOPTRA seeks to broaden the evaluated population, boosting participation rates and bypassing age screening thresholds. This action is part of the Cancer Mission cluster of projects on ‘Prevention, including Screening’.

Official data · CORDIS · synced 2026-10-17 10:16 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).